Both quantity and price rise, a big turn in the centralized purchase of consumables across the country? Domestic machinery enterprises break the situation and establish momentum!
2022-12-13
Announcement of results of continued coronary stent collection
Two new enterprises are shortlisted!
The threshold for the selection of products for this continued procurement was lowered, and the overall price of the enterprise’s products was raised orderly. This time, 14 products were selected, and 10 enterprises won the bid, including 3 foreign enterprises and 7 domestic enterprises.
Compared with the first centralized purchase, there are many points to be seen in this continuous purchase.
First of all, from the price point of view, the maximum effective quotation for this continuous purchase was not only increased, but also the incidental service fee was newly set. The average price increases of Class A, Class B and Class C were 21.01%, 42.36% and 18.87% respectively. The lowest price of the first centralized purchase was the Excrossal Xinyao bracket in Jiwei， Shandong Province, and the quotation was as low as 469 yuan. The lowest price of this centralized purchase was the proposed winning price of minimally invasive products, which was 730 yuan, and the lowest winning price has increased by 55%.
Many insiders in the industry said that the “floor price” of the first centralized purchase is partially recalled, and the product price gradually returned to rationality.
Secondly, from the perspective of demand, the total demand in 2020 was 1 million. This year, the demand rose to 1.865 million sets. 1288 new institutions joined the centralized procurement force. In 2021, the actual shipment of the winning enterprises was 1.69 million sets. From the perspective of the implementation resulted in 2021, the demand for PCI surgery after the centralized procurement of coronary stents significantly released.
Compared with the last centralized purchase, the selected enterprises have two more important new faces: Sano Medical and Abbott.
A total of two new products of Sinocare won the bid. HT Supreme was included in Category A for 779 yuan, and HT Infinity was included in Category B for 839 yuan. Abbott has reported that the products with the highest price limit have entered Class C, and Abbott has always been pursuing high profits as its basic strategy.
Jiang Changsong, Assistant Director of the National Institute for Health Security Research and Director of the Price Recruitment Office of the Capital Medical University, said: There are three highlights of this renewal procurement.
Firstly, hospitals are more active in reporting volumes; compared to two years ago, the number of medical institutions participating in this successive procurement has increased by 50%, the demand for stents has increased by 70% and the proportion of procurement with volume has increased to 95%.
Secondly, enterprises’ expectations are more stable; this successive procurement has simplified the procurement rules, stipulating that quotations not higher than the highest effective declared price can be qualified to be selected, i.e. RMB798 for coronary stents and RMB50 for accompanying services, fully guaranteeing that enterprises can be qualified to be selected; the procurement cycle has been changed from 2 years to 3 years, bringing nearly RMB5 billions of large orders for 11 enterprises at one time and ensuring the stability of the market pattern in a longer period of time.
Thirdly, the link between quantity and price is clearer; the products to be selected are divided into three categories, A, B and C, in order of quotation from lowest to highest, with the lower the price the higher the proportion of the share obtained and the more volume to be allocated available.
It can be seen that the pattern of national procurement is taking shape and developing steadily.
China is encouraging China end uses for more domestic products in latest years. Thus, more and more overseas manufacturers are planning localization in China. BradyKnows localization team has extensive experiences in facility establishment, audit, supplier evaluation, manufacturing, registration, and marketing in China. Pls feel free to let us know any questions on China entry via info@bradyknowsmedical.com
